What Is the MMP-9 Test and Why Is It Used?

An MMP-9 test measures the level of matrix metalloproteinase-9, an enzyme your body produces to break down and remodel the structural scaffolding between cells. The test shows up most often in eye clinics, where a quick in-office version helps diagnose inflammatory dry eye disease, but researchers and clinicians also measure MMP-9 in blood, sputum, and other body fluids to gauge inflammation linked to heart disease, stroke, inflammatory bowel disease, and several other conditions. The reason one enzyme matters in so many different settings comes down to what MMP-9 actually does and how its levels change when tissue damage and inflammation are underway.

What MMP-9 Does and Why Its Levels Matter

MMP-9 belongs to a family of enzymes that chew through proteins in the extracellular matrix, the mesh of collagen, elastin, and other structural molecules that holds tissues together. It plays a role in normal processes like wound repair, blood vessel formation, and immune cell movement through tissue. It also activates certain inflammatory signaling molecules, which is why it keeps showing up in disease states where inflammation is part of the problem.

Your body keeps MMP-9 in check through a system of natural inhibitors called TIMPs (tissue inhibitors of metalloproteinases). When MMP-9 is first released from cells, it comes out in an inactive form. Other enzymes have to clip part of it off before it becomes active. Once active, TIMP molecules can bind to it and shut it down. When the balance tips toward too much active MMP-9 and not enough TIMP, tissue breakdown accelerates. That imbalance is exactly what clinicians are looking for when they order the test.

MMP-9 is produced as an inactive precursor and can be activated by several other enzymes in the same family, with MMP-3 considered the most potent activator. Once activated, it degrades structural matrix proteins and triggers cytokines and chemokines that amplify inflammation and tissue remodeling.

The Dry Eye Test You Can Get in a Doctor’s Office

The most familiar version of the MMP-9 test for patients is a point-of-care immunoassay used in ophthalmology. The commercial version, called InflammaDry, works like a rapid pregnancy test: a small sample of tears is collected from the inside of the lower eyelid using a soft applicator, and within about ten minutes the device shows a positive or negative result for elevated MMP-9. Elevated levels indicate that inflammation on the surface of the eye is contributing to dry eye symptoms, which matters because not all dry eye is inflammatory and the treatment approach differs depending on the cause.

The clinical performance numbers are strong. In one study, InflammaDry showed a sensitivity of 85% and specificity of 94% for diagnosing inflammation-related dry eye, with a positive predictive value of 97%. That means when the test reads positive, the patient almost certainly has inflammatory dry eye rather than a purely tear-deficient form.¹ A separate study found that about 40% of confirmed dry eye patients tested positive for elevated MMP-9, identifying a subgroup with clinically significant ocular surface inflammation who would benefit from anti-inflammatory treatment rather than artificial tears alone.²

This distinction has real treatment implications. A patient whose dry eye is driven by inflammation typically needs prescription anti-inflammatory drops (cyclosporine or lifitegrast, for instance), not just over-the-counter lubricating drops. The MMP-9 test gives the eye doctor an objective data point for making that call rather than relying solely on symptom questionnaires and clinical appearance, both of which can be ambiguous in early or moderate disease.³

Heart Disease and Stroke Risk

Outside the eye clinic, MMP-9 measurement in blood is being studied as a cardiovascular risk marker. The logic is straightforward: MMP-9 breaks down structural proteins in blood vessel walls, and when it is overactive in the plaques that line arteries, those plaques become unstable and more likely to rupture. A ruptured plaque is what triggers most heart attacks and many strokes. Research has found that MMP-9 levels are higher in vulnerable plaques than in stable ones, raising the possibility that a blood test could flag people at higher risk of a cardiac event before it happens.⁴

A large study of patients with existing cardiovascular disease found that those who went on to die from a cardiovascular event had significantly higher baseline MMP-9 levels compared to those who survived. After adjusting for other clinical risk factors and medications, higher MMP-9 still predicted a greater likelihood of cardiovascular death.⁵ These findings position MMP-9 as a potential predictive biomarker, though it has not yet become a standard part of cardiac risk panels the way troponin or CRP have.

In the brain, MMP-9 is linked to blood-brain barrier breakdown during stroke. A study of stroke patients found that baseline MMP-9 levels predicted disruption of the blood-brain barrier at 24-hour follow-up, supporting the idea that the enzyme actively contributes to the leakiness that worsens brain injury after a stroke.⁶ This connection is particularly relevant for clinicians managing acute stroke treatment, where preserving the blood-brain barrier is a priority.

Inflammatory Bowel Disease

For people with Crohn’s disease or ulcerative colitis, a key clinical question is whether the gut lining is actually healing or just seems to be based on symptoms. Symptoms can improve while the intestinal wall remains inflamed, and that hidden inflammation predicts future flares. Endoscopy is the gold standard for checking mucosal healing, but it is invasive and cannot be done frequently.

Researchers have studied blood levels of an MMP-9 complex (NGAL-MMP-9) as a potential stand-in. In patients with active Crohn’s disease, NGAL-MMP-9 levels were roughly three times higher than in healthy controls. After treatment, levels dropped dramatically in patients who achieved complete endoscopic healing. At a cutoff of 45 ng/mL, the test showed 82% sensitivity for identifying complete endoscopic healing. Interestingly, among patients with active disease whose standard inflammation marker CRP was normal, over half still had elevated NGAL-MMP-9, suggesting this marker catches inflammation that CRP misses.⁷ MMPs more broadly have been recognized as potential biomarkers for disease activity in IBD and remain a focus of ongoing research.⁸

Lung Disease and Rheumatoid Arthritis

In chronic obstructive pulmonary disease (COPD), tissue destruction in the lungs is a defining feature. One study measuring sputum MMP-9 found that COPD patients had roughly five to six times higher MMP-9 levels than healthy nonsmokers, while healthy smokers fell in between. At the same time, TIMP-1, the natural inhibitor, was actually lower in COPD patients than in nonsmokers. The ratio of MMP-9 to TIMP-1 was about eight times higher in COPD patients compared to nonsmokers, painting a picture of unchecked enzymatic destruction of lung tissue.⁹

In rheumatoid arthritis, MMP-9 contributes to joint destruction in a way that goes beyond simple tissue breakdown. Research on synovial fibroblasts, the cells lining the joint capsule, found that suppressing MMP-9 also reduced the production of several major inflammatory cytokines and inactivated key inflammatory signaling pathways. This suggests that MMP-9 does not just degrade cartilage directly but also fuels the inflammatory cycle that drives ongoing damage.¹⁰

Cancer Research

MMP-9 has been widely studied in cancer because of its connection to three processes that tumors depend on: invasion of surrounding tissue, metastasis to distant sites, and the growth of new blood vessels to feed the tumor.¹¹ Elevated MMP-9 in blood or tumor tissue has been correlated with more aggressive disease in several cancer types. However, translating MMP-9 measurement into a clinically useful cancer screening or monitoring tool has been slow going. The enzyme is not specific to cancer; it rises in many inflammatory conditions, which limits its value as a standalone marker. Most cancer-related MMP-9 research focuses on its role as part of a panel of biomarkers or as a prognostic indicator within a known cancer diagnosis rather than a primary screening tool.

How the Test Is Performed

The method depends on what is being measured and why. In ophthalmology, the point-of-care immunoassay on tear fluid gives a qualitative positive-or-negative result with no lab processing needed. For blood-based measurement, clinicians and researchers use enzyme-linked immunosorbent assays (ELISAs), which quantify the exact concentration of MMP-9 in a sample. Older techniques like gelatin zymography can separate MMP-9 from related enzymes and distinguish the inactive precursor from the active form, but these are mostly reserved for research settings.¹²

One underappreciated practical issue is that sample handling can dramatically change results. MMP-9 concentrations are much higher in serum than in plasma. In serum samples collected in tubes containing a clot activator (the standard type used for many routine blood draws), MMP-9 levels were about threefold higher than in serum collected in plain tubes without the activator.¹³ This happens because platelets and white blood cells release MMP-9 during the clotting process, artificially inflating the reading.

Research comparing serum and plasma MMP-9 values found only a weak correlation between the two, meaning they are not interchangeable. For accurate results, plasma is the preferred sample type, and the specific anticoagulant used in the collection tube also matters.¹⁴ If you are being tested for MMP-9 in blood as part of a research protocol or a clinical workup, the tube the phlebotomist uses is not a trivial detail. And comparing MMP-9 results between labs or over time is only meaningful if the same sample type and collection method were used each time.

Wound Healing and Obstetric Applications

In wound care, MMP-9 tells a story about why some wounds refuse to close. Chronic wounds, such as diabetic ulcers, often have elevated MMP-9 levels. An animal study directly tested this by injecting MMP-9 at levels found in chronic wounds into standardized skin wounds. By day seven, the MMP-9-injected wounds were 12% larger than control wounds, and by day twelve the gap had widened to 25%. Examination of the tissue showed that MMP-9 was destroying collagen IV, a key protein that the migrating edge of new skin needs as scaffolding.¹⁵ Testing wound fluid for MMP-9 could eventually help wound care specialists identify patients who need MMP-9-lowering therapies rather than standard dressings alone, though this is still mostly in the research domain.

MMP-9 also shows up in obstetrics, specifically in the mechanics of how fetal membranes rupture. The amniotic sac is held together by a collagen-rich extracellular matrix, and MMP-9 is one of the enzymes that breaks it down at the right time. In normal term pregnancies, amniotic fluid MMP-9 concentrations jump sharply when membranes rupture spontaneously compared to when they remain intact.¹⁶ More concerning is the finding that MMP-9 expression is significantly elevated in the amniotic membranes of women who experience preterm premature rupture of membranes (PPROM), a major cause of premature birth.¹⁷ Whether MMP-9 testing could help predict or prevent PPROM is still an open question, but the biological link is clear.

Why Drugs Targeting MMP-9 Have Struggled

Given how much damage overactive MMP-9 causes across all these diseases, the obvious question is: why not just block it with a drug? The pharmaceutical industry tried exactly that, particularly in cancer, and the results were surprisingly bad. In the 1990s and early 2000s, a series of clinical trials tested broad-spectrum MMP inhibitors in various cancer types. Despite promising preclinical results, every trial failed to shrink tumors or improve survival, and some of the drugs caused severe side effects. One key reason emerged later: some MMPs actually fight tumors, and broad inhibitors knocked out the helpful enzymes along with the harmful ones.¹⁸

Researchers have had more nuanced success with drugs that happen to reduce MMP-9 as a secondary effect. Low-dose doxycycline, an antibiotic that also inhibits MMPs, reduced MMP-9 levels and lung injury in patients undergoing heart surgery requiring cardiopulmonary bypass.¹⁹ Doxycycline has also been studied in abdominal aortic aneurysms, where MMP-9-driven tissue destruction weakens the aortic wall, though the evidence for clinical benefit in human aneurysm patients remains unclear.²⁰ The broader lesson from the MMP-9 drug story is that the enzyme is deeply woven into both harmful and protective processes, and simply shutting it down creates as many problems as it solves.

MMP-9 in Pain and Complex Regional Pain Syndrome

A less well-known application involves MMP-9 testing in chronic pain conditions. In complex regional pain syndrome (CRPS), a debilitating condition that typically develops after an injury and involves disproportionate, persistent pain in a limb, researchers found that MMP-9 was elevated in skin biopsies from the affected limb. Higher MMP-9 levels on both the affected and unaffected sides correlated with greater CRPS severity, suggesting a systemic component rather than just local tissue damage. This kind of finding is still squarely in the research phase, but it points to MMP-9 as a potential severity marker in conditions where objective measures of disease burden are desperately needed.

The pattern across all of these conditions is consistent: MMP-9 rises when tissue is being damaged by inflammation, and measuring it gives clinicians a window into what is happening at a cellular level. Whether that window proves useful enough to become routine testing in cardiology, gastroenterology, or pain medicine depends on ongoing work to establish reference ranges, standardize collection methods, and demonstrate that knowing a patient’s MMP-9 level actually changes outcomes. In ophthalmology, at least, the test has already crossed that threshold.